疏肝健脾清热利湿法对非酒精性脂肪性肝炎肝功ALT、AST、GGT的临床研究
|
摘要
目的:通过临床病例收集,观察疏肝健脾清热利湿法治疗非酒精性脂肪性肝炎肝郁脾虚瘀血湿热内阻型的临床疗效,分析中药对NASH患者肝功(ALT、AST、γ-GT)的改善效果,从而为治疗NASH提供新的思路及治疗方法。
方法:1、选取2007年5月-2008年5月黑龙江中医药大学附属第一医院门诊及住院80例NASH患者,按中医辨证属于肝郁脾虚瘀血湿热内阻型,西医符合NASH的诊断标准。采用去组随机化法分为治疗组40例,对照组40例,两组在性别、年龄、病程、受试时症状等方面比较均无显著性差异(P＞0.05),具有可比性;2、治疗组:以中医理论为指导,根据疏肝健脾清热利湿法选药组方进行治疗;对照组选用东宝肝泰药进行治疗:3、观察两组在治疗前后肝功(ALT、AST、γ-GT)的变化情况,并做统计学分析,比较两者的疗效。
结果:治疗结束后,两组肝功均有恢复,治疗组有效率为89.47%,对照组有效率为79.49%,两组差异无统计学意义(P＞0.05).两组肝功各项指标ALT、AST、γ-GT均有下降,治疗组治疗后ALT 47.11±17.27,对照组治疗后ALT 66.51±18.31,两组有显著差异(P＜0.05);治疗组治疗后AST 40.76±15.60,对照组治疗后AST 58.10±14.94,两组有显著差异(P＜0.05);治疗组治疗后GGT 56.10±14.45,对照组治疗后γ-GT 42.57±5.71,两组有显著差异(P＜0.05)。试验期间无不良事件与不良反应发生。
结论:疏肝健脾清热利湿法治疗非酒精性脂肪性肝炎可以改善患者肝功指标中的ALT、AST、γ-GT,且疗效优于东宝肝泰组,安全性良好。
Title:A Clinical Study on the Treatment of Liver Depression Spleen Deficiency And Blood Stasis Damp-heat Stagnation Syndrome type of non-alcoholic steatohepatitis in the liver function with Shuganjianpi Qingrelishi method.
Objective:Through collecting clinical cases,to investigate Shuganjianpi Qingrelishi method of the treatment of NASH clinical efficacy and to analyze the effect of Chinese medicine on the treatment of NASH in the liver function(ALT、AST、γ-GT),thus to provide new ideas and treatment methods for the treatment of NASH.
Methods:1、To seclect 80 cases patients with Non-alcoholic steatohepatitis diseases who from May 2007 to May 2008 in the number one hospital of Heilongjiang Province Chinese medicine university inpatient and outpatient.The patients with NASH as the Chinese medicine theory is liver depression spleen deficiency and blood stasis damp-heat stagnation syndrome,and conforming to western medicine diagnose criterion.The patients were randomly divided into treatment group 40 cases,the control group 40 cases.Patients in the two group by gender,age,duration,symptoms tested at compared.There was no significant difference(P＞0.05),and comparabil-ity.2、The treatment group take the Chinese medicine theory as the instruction,and based on the principle of Shuganjianpi Qingrelishi method.The control group adoption Dongbao Gantai tablet treatment 3、In the course of treatment,the items that we had observed with all patients were glutamic pyruvic transaminase(ALT),glutamic oxaloacetic transaminase(AST),γglutamyltransferase(γ-GT),and do statical analysis, and compare the results.
Result:The total effective rate of improvement the function of liver of Chinese medicine in the treatment group is 89.47%after treatment,while it is 79.49%in the control group,the difference between the two groups is not significant,but there was significant difference in the level of ALT, AST,andγ-GT.between the two group,the level of ALT trial group is 47.11±17.27,while the conrtol group is 66.51±18.31(P＞0.05);the level of AST trial group is 40.76±15.60,while the conrtol group is 58.10±14.94 (P＞0.05);the level of GGT trial group is 38.084-14.99,while the conrtol group is 56.10±14.54(P＞0.05).During the period of the clinical study has not adverse events and adverse reaction occured.
Conclusion:the Treatment of non-alcoholic steatohepatitis with Shuganjianpi Qingrelishi Method could improve the function of liverALT、AST,γ-GT,the effect is superior to the conrtol group.The clinical study is good safety.
方法:1、选取2007年5月-2008年5月黑龙江中医药大学附属第一医院门诊及住院80例NASH患者,按中医辨证属于肝郁脾虚瘀血湿热内阻型,西医符合NASH的诊断标准。采用去组随机化法分为治疗组40例,对照组40例,两组在性别、年龄、病程、受试时症状等方面比较均无显著性差异(P＞0.05),具有可比性;2、治疗组:以中医理论为指导,根据疏肝健脾清热利湿法选药组方进行治疗;对照组选用东宝肝泰药进行治疗:3、观察两组在治疗前后肝功(ALT、AST、γ-GT)的变化情况,并做统计学分析,比较两者的疗效。
结果:治疗结束后,两组肝功均有恢复,治疗组有效率为89.47%,对照组有效率为79.49%,两组差异无统计学意义(P＞0.05).两组肝功各项指标ALT、AST、γ-GT均有下降,治疗组治疗后ALT 47.11±17.27,对照组治疗后ALT 66.51±18.31,两组有显著差异(P＜0.05);治疗组治疗后AST 40.76±15.60,对照组治疗后AST 58.10±14.94,两组有显著差异(P＜0.05);治疗组治疗后GGT 56.10±14.45,对照组治疗后γ-GT 42.57±5.71,两组有显著差异(P＜0.05)。试验期间无不良事件与不良反应发生。
结论:疏肝健脾清热利湿法治疗非酒精性脂肪性肝炎可以改善患者肝功指标中的ALT、AST、γ-GT,且疗效优于东宝肝泰组,安全性良好。
Title:A Clinical Study on the Treatment of Liver Depression Spleen Deficiency And Blood Stasis Damp-heat Stagnation Syndrome type of non-alcoholic steatohepatitis in the liver function with Shuganjianpi Qingrelishi method.
Objective:Through collecting clinical cases,to investigate Shuganjianpi Qingrelishi method of the treatment of NASH clinical efficacy and to analyze the effect of Chinese medicine on the treatment of NASH in the liver function(ALT、AST、γ-GT),thus to provide new ideas and treatment methods for the treatment of NASH.
Methods:1、To seclect 80 cases patients with Non-alcoholic steatohepatitis diseases who from May 2007 to May 2008 in the number one hospital of Heilongjiang Province Chinese medicine university inpatient and outpatient.The patients with NASH as the Chinese medicine theory is liver depression spleen deficiency and blood stasis damp-heat stagnation syndrome,and conforming to western medicine diagnose criterion.The patients were randomly divided into treatment group 40 cases,the control group 40 cases.Patients in the two group by gender,age,duration,symptoms tested at compared.There was no significant difference(P＞0.05),and comparabil-ity.2、The treatment group take the Chinese medicine theory as the instruction,and based on the principle of Shuganjianpi Qingrelishi method.The control group adoption Dongbao Gantai tablet treatment 3、In the course of treatment,the items that we had observed with all patients were glutamic pyruvic transaminase(ALT),glutamic oxaloacetic transaminase(AST),γglutamyltransferase(γ-GT),and do statical analysis, and compare the results.
Result:The total effective rate of improvement the function of liver of Chinese medicine in the treatment group is 89.47%after treatment,while it is 79.49%in the control group,the difference between the two groups is not significant,but there was significant difference in the level of ALT, AST,andγ-GT.between the two group,the level of ALT trial group is 47.11±17.27,while the conrtol group is 66.51±18.31(P＞0.05);the level of AST trial group is 40.76±15.60,while the conrtol group is 58.10±14.94 (P＞0.05);the level of GGT trial group is 38.084-14.99,while the conrtol group is 56.10±14.54(P＞0.05).During the period of the clinical study has not adverse events and adverse reaction occured.
Conclusion:the Treatment of non-alcoholic steatohepatitis with Shuganjianpi Qingrelishi Method could improve the function of liverALT、AST,γ-GT,the effect is superior to the conrtol group.The clinical study is good safety.
引文
[1]尤松鑫 脂肪肝的中医证治[J].南京中医药大学学报 1995.15(1):16
[2]施军平,王新光,娄国强.脂肪肝辨证分型与胰岛素抵抗的相关性研究[J].浙江中医学院学报,2003;27(4):32-34.
[3]魏华凤,季光,邢练军.脂肪肝辨证分型规律的初步研究[J].辽宁中医杂志,2002;29(11):655-656.
[4]王骏,魏玮.脂肪肝的中医辨证分型与血清生化指标的关系[J]..中西医结合肝病杂志,2004;14(6):371-372.
[5]缪锡民,非酒精性脂肪性肝炎的中医分型证治.浙江中医学院学报,1998,22(6):24.
[6]曹建春.辨证治疗脂肪肝60例疗效观察[J].浙江中西医结合杂志,2002,12(8):490.
[7]裴道灵,周玉琴,张先.辨证论治脂肪肝168例[J].河南中医,2001,21(50):39
[8]何国强、周世印 脂肪肝从湿毒论治初探[J].浙江中医杂志,2005,(6):254-255
[9]王兵,霍清萍,马建慧.舒肝活血化痰方治疗非酒精性脂肪肝炎的临床观察[J]上海中医药杂志。2005。39(7):23-24.
[10]吴圣明、李远华.“柴胡活血汤”治疗非乙醇性脂肪性肝炎56例[J].江苏中医药,2003,24(12):20.
[11]李占平.“温通化浊汤”治疗非酒精性脂肪性肝炎57例临床观察[J].江西中医药,2004,25(10):36.
[12]赵和平、段晓燕,“降脂益肝冲剂”治疗非酒精性脂肪性肝炎的实验研究[J]。Drug evaluation,2007 Vol.4(27):114.
[13]黄志平,李伏娥,朱清云,等.茵陈越鞠汤治疗非酒精性脂肪性肝炎的临床观察[J].中国中医药科技,2004;11(6):371-372.
[14]姜祖恒,王建勇.疏肝泄浊汤治疗非酒精性脂肪肝52例[J].实用中医药杂志,2006;22(2):80-81.
[15]陈黎、蒋阳昆、蔡晏波 从痰论治非酒精性脂肪性肝炎痰瘀证对纤溶状态的影响[J].中国中西医结合杂志,2006,26(12):1090-1091
[16]付丽,卢宁,韩玉珍.祛瘀除痰补虚方治疗脂肪性肝炎30例临床观察[J].中国中医 药科技,2003,10(2):124.
[17]辛伟,李晓东,廖远芬.清热化痰活血法治疗非酒精性脂肪肝 30例.中西医结合肝病杂志,2005;15(5):303-304.
[18]苏经格.四君子汤加味治疗非酒精性脂肪肝临床观察.中国医药学报,2004;19(8):494-495.
[19]冯立.化痰理肝方治疗非酒精性脂肪性肝炎60例.中西医结合肝病杂志,2001,1(5):304.
[20]吴佳玉,江南,黄仁刚 当飞利肝宁治疗非酒精性脂肪性肝炎的临床研究[J]四川省卫生管理干部学院学报,2008,27(3):192-193
[21]李向阳 脂必泰胶囊治疗非酒精性脂肪性肝炎45例[J].陕西中医 2008,29(12):1643
[22]韩素萍 田锋亮 王强 舒肝健脾化瘀颗粒治疗非酒精性脂肪性肝炎的临床观察[J]2008,10,(9):71-72
[23]李荣洲,应卫星,朱畴文 大黄酸对实验性非酒精性脂肪型肝炎的治疗作用[J].中国临床药理学与治疗学,2007,12(8):923-926
[24]严茂祥 陈芝云 施军平 刘庆生 何蓓 理气化痰祛瘀法对非酒精性脂肪型肝炎大鼠纤溶酶原激活物及其抑制物的影响.[J].中医杂志2006.47(10):775-777
[25]赵晓琴 张霖 排毒降脂合剂对非酒精性脂肪型肝炎保护作用机制实验研究[J].辽宁中医药杂志2007,34(5):677
[26]郭选贤 导痰汤治疗高脂血症的实验研究[J]中国医药学报 2000,15(3):71
[27]祁培宏 朱莉芳 刘平 消脂保肝饮抗大鼠脂肪肝作用的研究[J].中西医结合肝病杂志 2000,10(5):71
[28]寺本民生,肥胖与脂肪肝[J].日本医学介绍,1995,16(10):440
[29]Harrison SA,Kadakia S,Lang KA,et al.Am J Gastroenterol,2002;97:2714-2724
[30]艾正林,陈东风.非酒精性脂肪肝与胰岛素抵抗.现代医药卫生,2005;22(1):33.
[31]裴强,王晓素,王宪波.非酒精性脂肪性肝炎发病机制的研究进展[J]临床肝胆病杂志,2008,24(4):304
[32]MeCullough AJ.Update on nonalcoholic fatty liver disease.J Clin Castroenterol,2002,34:255
[33]曾民德.脂肪肝发病机制及其“二次打击”假设[J]中华消化杂志,2002,22:167-168
[34]聂青和,王全楚.过氧化酶体β氧化与脂肪性肝炎[J]肝脏,2001,6:190-191
[35]付真烈,刘胜利,王敏.氧自由基造成肝细胞损害的机理[J]临床肝胆病杂志,1996,12:181-182
[36]Day CP.Nonalcoholic steatohep titis(NASH):where are we now and where are we going[J]Gut,2002,50:585.
[37]Okamoto Y,Tanaka S,Haga Y.Enhanced GLUT2 gene expession inan oleic acid2induced in vitro fatty iver mode[J].Hepatol Hes,2002,23(2):138.
[38]Inui Y,Keno Y,Fukuda K,et al.Modulation of apolipop rotein geneexp ression in fatty liver of obese rats:enhanced APOA2Ⅳ,but no APOB exp ression by a high sucrose diet[J].Int J Obes RelatMetab Disord,1997,2(3):231.
[39]郭津生,沈沪佳 非酒精性脂肪性肝炎发病机制的研究进展[J],国外医学消化系统分册,2005,5:271-272
[40]GeorgeDK,GoldwumS,MacdonaldGA,et al.Increased hepatic iron con-centration in nonalcoholic steatohepatitis associated with increased fibrosis.Gastroenterology,1998;114(2):311-318.
[41]Bacon BR,Powell LM,Adams PC,et al.Molecular medicine and hemochromatosis:atthe cross roads.Gastroenterology,1999;116(1):193-207.
[42]鲁超 邹宇宏 王建清 李俊 非酒精性脂肪型肝炎的病因及发病机制研究进展[J].安徽医药,2006,10(2):81
[43]范建高,非酒精性脂肪性肝炎[J],现代医药卫生,2001,7:511
[44]Hultacrantz R,Glaumann H,Lindbe rg G.Liver investigation in 149asymptomatic patients with moderately elevated activaties of serum aminotransferases.Stand,Gastroenterol 1986;21:109-113
[45]李国钦 非酒精性脂肪肝炎的临床研究进展[J],临床肝胆病杂志,2004,20(2):121
[46]李锋,范建高,非酒精性脂肪肝炎[J],现代医药卫生,2004,20(19):1995,
[47]范建高非酒精性脂肪肝炎[J],现代医药卫生,2001,17(7):511
[48]中华肝脏病学会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊断标准.肝脏,2002,7(4):附页2
[49]刘海,陆伦根,非酒精性脂肪性肝炎的治疗新进展[J]胃肠病学,2006,1:59
[50]杜文民 非酒精性脂肪性肝病治疗药物的评价[J]药品评价2007,4(2):71-73
[51]Marchesini G Brizi M,Bianchi G,et al,Metformin in nonalcolie steatohepatitis.Lancet,2001,358:893
[52]丁效蕙 赵景民 非酒精性脂肪性肝炎的发病机制及治疗的研究进展[J],世界华人消化杂志,2005,13(3):371-375
[53]展玉涛 非酒精性脂肪性肝炎药物治疗的临床研究进展[J],临床荟萃,2006,21(4):290-291
[54]Hasegawa T,Yoneda M,Nakamura K,et al.Plasma transforming growt factor.beta level and efieaey of alpha-toeopheml in patients with nonal-coholic steatohepatitis.Aliment Pharmarol Ther,2001,(15)1667
[55]孟二红,赵景民,非酒精性脂肪性肝炎的研究进展[J],世界华人消化杂志,2002,10:1208
[56]Gulbahar O,KarasuZA,ErsozG,et al.Treatment of non-Aleoholic esteatohepatitiswith N-acetylcysteine.Gastroen-terology,2000,1118:A1444
[57]刘梅陆伦根 非酒精性脂肪性肝病的治疗新进展胃肠病学2006年第11卷第1期:59-61
[58]沈镭 陆伦根 房静远 非酒精性脂肪性肝炎药物治疗的循证评价[J]胃肠病学,2009,14(1):47
[59]潘俊,陈岳祥,非酒精性脂肪性肝炎的治疗进展[J],现代医药卫生,2003,5:543
[60]沈沪佳,郭津生 非酒精性脂肪性肝炎的治疗[J]中国临床医学,2005,12(6):1184
[61]Santos VN,Lanzoni VP,Szejnfeld J,etal.Arandomized double-blind study of the shorttime treatment of obese patiens with nonalcolic steatohepatitis.Wit hurdexycholic acid,braz J Med Biol Res,2003,36:723-729
[62]肖文斌,贾万金,刘玉兰,非酒精性脂肪性肝炎的研究进展[J],临床肝病杂志,2001,2:73
[63]张启伟.决明子现代研究概况[J].国外医学.中医中药分册,1995,17(1):6.
[64]郭绍举,刘禹翔,谢伟,等.中医药抗肝纤维化的近况[J].中西医结合肝病杂志,2002,12(1):62.
[65]田利鲜 柴胡的药理作用和临床运用[J]湖北中医杂志,2008,30(1):59
[66]张光成,方恩鸣.葛根异黄酮的抗氧化作用.中药材,1997,20(7):358
[67]董岩,王新芳,崔长军,等.茵陈蒿的化学成分和药理作用的研究进展[J].时珍国医国药,2008,19(4):874-876.
[68]侯世荣,等·黄芪口服液治疗慢性肝炎的疗效观察·中草药,2000,31(10):767
[69]焦河玲,黄兆胜,贾建功.大黄素对四氯化碳损伤原代培养大鼠肝细胞的保护作用[J].河南中医,2000,20(5):20-22.
[70]张喜平 齐丽丽 刘达人三七及其有效成分的药理作用研究现状[J]医学研究杂志,2007,36(4):97
[71]阎君宝,金龙,汪江碧,等.决明子抑制营养性肥胖大鼠体重增加的作用.中药材,2004;27(4):281-284.
[72]缪锡民 脂肪肝的中医分型证治,浙江中医学院学报,1998,12(6):24
[73]江庆澜,李瑜元,潘锦瑶,等.虎杖提取液对非酒精性脂肪肝大鼠肿瘤坏死因子α基因表达的影响.中药材,2005;28(10):917-920.
[74]Abe I,Seki T,Noguchi H,et al.Galloyl esters from rhubarb are potentinhibitors of squalene epoxidase,a key enzyme in cholesterol biosynthe-sis[J].Planta Med,2000,66(8):753-756.
[75]李义奎.中药药理学[M].北京:中国中医药出版社,1992:126-126.
[76]刘彬,许宏大.苦丁茶降血脂的实验及临床研究[J].护理研究,2005,19(1):21.
[77]向华林,许宏大,田文艺,等.中国皋芦(苦丁)茶降脂作用的试验研究[J].中国中药杂志,1994,19(8):497.
[78]王文俊,吴咸中,姚智,等.大黄素、丹参素对单核细胞分泌炎性细胞因子的调节[J].中国免疫学杂志,1995,11(6):370.
[79]董艳,乔建成,张晚丽,等.苦丁茶药效学实验研究[J].牡丹江医学院学报,2001,22(2):6.
[80]董丽萍.葛根对免疫机制的作用.中国药理学报,1998,19(4):339
[81]郭颖杰,等·黄芪水煎液对人黑色素瘤细胞A375-S2的杀伤作用.中草药,2001,(31):114
[82]贺怀新.中药免疫学[M].北京:人民军医出版社,2002:12.
[83]朱兆荣,李玉强,等.补骨脂总黄酮抗氧化作用研究.中国兽药杂志,2005;39(2):18-20
[84]赵武述,张玉琴,等.植物多糖提取物致有丝分裂反应的分析.中华微生物和免疫学杂志,1991;11(6):381-385
[2]施军平,王新光,娄国强.脂肪肝辨证分型与胰岛素抵抗的相关性研究[J].浙江中医学院学报,2003;27(4):32-34.
[3]魏华凤,季光,邢练军.脂肪肝辨证分型规律的初步研究[J].辽宁中医杂志,2002;29(11):655-656.
[4]王骏,魏玮.脂肪肝的中医辨证分型与血清生化指标的关系[J]..中西医结合肝病杂志,2004;14(6):371-372.
[5]缪锡民,非酒精性脂肪性肝炎的中医分型证治.浙江中医学院学报,1998,22(6):24.
[6]曹建春.辨证治疗脂肪肝60例疗效观察[J].浙江中西医结合杂志,2002,12(8):490.
[7]裴道灵,周玉琴,张先.辨证论治脂肪肝168例[J].河南中医,2001,21(50):39
[8]何国强、周世印 脂肪肝从湿毒论治初探[J].浙江中医杂志,2005,(6):254-255
[9]王兵,霍清萍,马建慧.舒肝活血化痰方治疗非酒精性脂肪肝炎的临床观察[J]上海中医药杂志。2005。39(7):23-24.
[10]吴圣明、李远华.“柴胡活血汤”治疗非乙醇性脂肪性肝炎56例[J].江苏中医药,2003,24(12):20.
[11]李占平.“温通化浊汤”治疗非酒精性脂肪性肝炎57例临床观察[J].江西中医药,2004,25(10):36.
[12]赵和平、段晓燕,“降脂益肝冲剂”治疗非酒精性脂肪性肝炎的实验研究[J]。Drug evaluation,2007 Vol.4(27):114.
[13]黄志平,李伏娥,朱清云,等.茵陈越鞠汤治疗非酒精性脂肪性肝炎的临床观察[J].中国中医药科技,2004;11(6):371-372.
[14]姜祖恒,王建勇.疏肝泄浊汤治疗非酒精性脂肪肝52例[J].实用中医药杂志,2006;22(2):80-81.
[15]陈黎、蒋阳昆、蔡晏波 从痰论治非酒精性脂肪性肝炎痰瘀证对纤溶状态的影响[J].中国中西医结合杂志,2006,26(12):1090-1091
[16]付丽,卢宁,韩玉珍.祛瘀除痰补虚方治疗脂肪性肝炎30例临床观察[J].中国中医 药科技,2003,10(2):124.
[17]辛伟,李晓东,廖远芬.清热化痰活血法治疗非酒精性脂肪肝 30例.中西医结合肝病杂志,2005;15(5):303-304.
[18]苏经格.四君子汤加味治疗非酒精性脂肪肝临床观察.中国医药学报,2004;19(8):494-495.
[19]冯立.化痰理肝方治疗非酒精性脂肪性肝炎60例.中西医结合肝病杂志,2001,1(5):304.
[20]吴佳玉,江南,黄仁刚 当飞利肝宁治疗非酒精性脂肪性肝炎的临床研究[J]四川省卫生管理干部学院学报,2008,27(3):192-193
[21]李向阳 脂必泰胶囊治疗非酒精性脂肪性肝炎45例[J].陕西中医 2008,29(12):1643
[22]韩素萍 田锋亮 王强 舒肝健脾化瘀颗粒治疗非酒精性脂肪性肝炎的临床观察[J]2008,10,(9):71-72
[23]李荣洲,应卫星,朱畴文 大黄酸对实验性非酒精性脂肪型肝炎的治疗作用[J].中国临床药理学与治疗学,2007,12(8):923-926
[24]严茂祥 陈芝云 施军平 刘庆生 何蓓 理气化痰祛瘀法对非酒精性脂肪型肝炎大鼠纤溶酶原激活物及其抑制物的影响.[J].中医杂志2006.47(10):775-777
[25]赵晓琴 张霖 排毒降脂合剂对非酒精性脂肪型肝炎保护作用机制实验研究[J].辽宁中医药杂志2007,34(5):677
[26]郭选贤 导痰汤治疗高脂血症的实验研究[J]中国医药学报 2000,15(3):71
[27]祁培宏 朱莉芳 刘平 消脂保肝饮抗大鼠脂肪肝作用的研究[J].中西医结合肝病杂志 2000,10(5):71
[28]寺本民生,肥胖与脂肪肝[J].日本医学介绍,1995,16(10):440
[29]Harrison SA,Kadakia S,Lang KA,et al.Am J Gastroenterol,2002;97:2714-2724
[30]艾正林,陈东风.非酒精性脂肪肝与胰岛素抵抗.现代医药卫生,2005;22(1):33.
[31]裴强,王晓素,王宪波.非酒精性脂肪性肝炎发病机制的研究进展[J]临床肝胆病杂志,2008,24(4):304
[32]MeCullough AJ.Update on nonalcoholic fatty liver disease.J Clin Castroenterol,2002,34:255
[33]曾民德.脂肪肝发病机制及其“二次打击”假设[J]中华消化杂志,2002,22:167-168
[34]聂青和,王全楚.过氧化酶体β氧化与脂肪性肝炎[J]肝脏,2001,6:190-191
[35]付真烈,刘胜利,王敏.氧自由基造成肝细胞损害的机理[J]临床肝胆病杂志,1996,12:181-182
[36]Day CP.Nonalcoholic steatohep titis(NASH):where are we now and where are we going[J]Gut,2002,50:585.
[37]Okamoto Y,Tanaka S,Haga Y.Enhanced GLUT2 gene expession inan oleic acid2induced in vitro fatty iver mode[J].Hepatol Hes,2002,23(2):138.
[38]Inui Y,Keno Y,Fukuda K,et al.Modulation of apolipop rotein geneexp ression in fatty liver of obese rats:enhanced APOA2Ⅳ,but no APOB exp ression by a high sucrose diet[J].Int J Obes RelatMetab Disord,1997,2(3):231.
[39]郭津生,沈沪佳 非酒精性脂肪性肝炎发病机制的研究进展[J],国外医学消化系统分册,2005,5:271-272
[40]GeorgeDK,GoldwumS,MacdonaldGA,et al.Increased hepatic iron con-centration in nonalcoholic steatohepatitis associated with increased fibrosis.Gastroenterology,1998;114(2):311-318.
[41]Bacon BR,Powell LM,Adams PC,et al.Molecular medicine and hemochromatosis:atthe cross roads.Gastroenterology,1999;116(1):193-207.
[42]鲁超 邹宇宏 王建清 李俊 非酒精性脂肪型肝炎的病因及发病机制研究进展[J].安徽医药,2006,10(2):81
[43]范建高,非酒精性脂肪性肝炎[J],现代医药卫生,2001,7:511
[44]Hultacrantz R,Glaumann H,Lindbe rg G.Liver investigation in 149asymptomatic patients with moderately elevated activaties of serum aminotransferases.Stand,Gastroenterol 1986;21:109-113
[45]李国钦 非酒精性脂肪肝炎的临床研究进展[J],临床肝胆病杂志,2004,20(2):121
[46]李锋,范建高,非酒精性脂肪肝炎[J],现代医药卫生,2004,20(19):1995,
[47]范建高非酒精性脂肪肝炎[J],现代医药卫生,2001,17(7):511
[48]中华肝脏病学会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊断标准.肝脏,2002,7(4):附页2
[49]刘海,陆伦根,非酒精性脂肪性肝炎的治疗新进展[J]胃肠病学,2006,1:59
[50]杜文民 非酒精性脂肪性肝病治疗药物的评价[J]药品评价2007,4(2):71-73
[51]Marchesini G Brizi M,Bianchi G,et al,Metformin in nonalcolie steatohepatitis.Lancet,2001,358:893
[52]丁效蕙 赵景民 非酒精性脂肪性肝炎的发病机制及治疗的研究进展[J],世界华人消化杂志,2005,13(3):371-375
[53]展玉涛 非酒精性脂肪性肝炎药物治疗的临床研究进展[J],临床荟萃,2006,21(4):290-291
[54]Hasegawa T,Yoneda M,Nakamura K,et al.Plasma transforming growt factor.beta level and efieaey of alpha-toeopheml in patients with nonal-coholic steatohepatitis.Aliment Pharmarol Ther,2001,(15)1667
[55]孟二红,赵景民,非酒精性脂肪性肝炎的研究进展[J],世界华人消化杂志,2002,10:1208
[56]Gulbahar O,KarasuZA,ErsozG,et al.Treatment of non-Aleoholic esteatohepatitiswith N-acetylcysteine.Gastroen-terology,2000,1118:A1444
[57]刘梅陆伦根 非酒精性脂肪性肝病的治疗新进展胃肠病学2006年第11卷第1期:59-61
[58]沈镭 陆伦根 房静远 非酒精性脂肪性肝炎药物治疗的循证评价[J]胃肠病学,2009,14(1):47
[59]潘俊,陈岳祥,非酒精性脂肪性肝炎的治疗进展[J],现代医药卫生,2003,5:543
[60]沈沪佳,郭津生 非酒精性脂肪性肝炎的治疗[J]中国临床医学,2005,12(6):1184
[61]Santos VN,Lanzoni VP,Szejnfeld J,etal.Arandomized double-blind study of the shorttime treatment of obese patiens with nonalcolic steatohepatitis.Wit hurdexycholic acid,braz J Med Biol Res,2003,36:723-729
[62]肖文斌,贾万金,刘玉兰,非酒精性脂肪性肝炎的研究进展[J],临床肝病杂志,2001,2:73
[63]张启伟.决明子现代研究概况[J].国外医学.中医中药分册,1995,17(1):6.
[64]郭绍举,刘禹翔,谢伟,等.中医药抗肝纤维化的近况[J].中西医结合肝病杂志,2002,12(1):62.
[65]田利鲜 柴胡的药理作用和临床运用[J]湖北中医杂志,2008,30(1):59
[66]张光成,方恩鸣.葛根异黄酮的抗氧化作用.中药材,1997,20(7):358
[67]董岩,王新芳,崔长军,等.茵陈蒿的化学成分和药理作用的研究进展[J].时珍国医国药,2008,19(4):874-876.
[68]侯世荣,等·黄芪口服液治疗慢性肝炎的疗效观察·中草药,2000,31(10):767
[69]焦河玲,黄兆胜,贾建功.大黄素对四氯化碳损伤原代培养大鼠肝细胞的保护作用[J].河南中医,2000,20(5):20-22.
[70]张喜平 齐丽丽 刘达人三七及其有效成分的药理作用研究现状[J]医学研究杂志,2007,36(4):97
[71]阎君宝,金龙,汪江碧,等.决明子抑制营养性肥胖大鼠体重增加的作用.中药材,2004;27(4):281-284.
[72]缪锡民 脂肪肝的中医分型证治,浙江中医学院学报,1998,12(6):24
[73]江庆澜,李瑜元,潘锦瑶,等.虎杖提取液对非酒精性脂肪肝大鼠肿瘤坏死因子α基因表达的影响.中药材,2005;28(10):917-920.
[74]Abe I,Seki T,Noguchi H,et al.Galloyl esters from rhubarb are potentinhibitors of squalene epoxidase,a key enzyme in cholesterol biosynthe-sis[J].Planta Med,2000,66(8):753-756.
[75]李义奎.中药药理学[M].北京:中国中医药出版社,1992:126-126.
[76]刘彬,许宏大.苦丁茶降血脂的实验及临床研究[J].护理研究,2005,19(1):21.
[77]向华林,许宏大,田文艺,等.中国皋芦(苦丁)茶降脂作用的试验研究[J].中国中药杂志,1994,19(8):497.
[78]王文俊,吴咸中,姚智,等.大黄素、丹参素对单核细胞分泌炎性细胞因子的调节[J].中国免疫学杂志,1995,11(6):370.
[79]董艳,乔建成,张晚丽,等.苦丁茶药效学实验研究[J].牡丹江医学院学报,2001,22(2):6.
[80]董丽萍.葛根对免疫机制的作用.中国药理学报,1998,19(4):339
[81]郭颖杰,等·黄芪水煎液对人黑色素瘤细胞A375-S2的杀伤作用.中草药,2001,(31):114
[82]贺怀新.中药免疫学[M].北京:人民军医出版社,2002:12.
[83]朱兆荣,李玉强,等.补骨脂总黄酮抗氧化作用研究.中国兽药杂志,2005;39(2):18-20
[84]赵武述,张玉琴,等.植物多糖提取物致有丝分裂反应的分析.中华微生物和免疫学杂志,1991;11(6):381-385